Business
Director Dealings and Issue of Equity
Director Dealings and Issue of Equity.
About this update from Allergy Therapeutics Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 5729B\n Allergy Therapeutics PLC\n 09 October 2020\n \n \n \n \n \n \n \n \n \n \n Allergy Therapeutics plc\n \n \n (\"Allergy Therapeutics\" or the \"Company\")\n \n \n \n \n \n Director Dealings and Issue of Equity\n \n \n \n \n \n 9 October 2020 \n - Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, announces that Manuel Llobet, Chief Executive Officer, has \n exercised 2,577,923 options over ordinary shares of 0.1 pence each in the capital of the Company (\"Ordinary Shares\") (\"Exercise\") in aggregate, held under the terms of the Company's Long Term Incentive Plan. The 2,577,923 new Ordinary Shares issued pursuant to the Exercise (\"New Ordinary Shares \") have been sold by \n Mr Llobet\n at a price of 15 pence per ordinary share (\"Sale\"). The sold shares represent approximately 28.6% of Mr \n Llobet\n 's total equity and option holdings in the Company's equity. This share sale is the first sale of any of Mr \n Llobet\n 's equity in the Company since joining in 2009 and he has no current intention of making further sales of Allergy Therapeutics shares.\n \n \n Following the Exercise and Sale, \n Mr \n Llobet\n 's \n holding of Ordinary Shares remains unchanged at a total of \n 3,325,000 \n Ordinary Shares, representing \n 0.52\n % of the enlarged issued share capital of the Company and following the Exercise, \n Mr \n Llobet\n \n holds a further \n 3,122,500 \n options and conditional awards over \n Company's ordinary shares of 0.1 pence each\n .\n \n \n Total voting rights\n \n \n The \n 2,577,923\n New Ordinary Shares will be allocated out of the ordinary shares pursuant to the block listing announced on 21 November 2017. The New Ordinary Shares will rank pari passu with the existing shares of the Company. Following Admission, the Company's issued ordinary share capital will consist of \n 639,863,727 \n ordinary shares. The Company does not hold any shares in treasury. Therefore, the total number of ordinary shares with voting rights in the Company following Admission will be \n 639,863,727\n .\n \n \n The above figure of \n 639,863,727 \n may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest...